
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/908588/publications.pdf Version: 2024-02-01



#	ARTICLE	IF	CITATIONS
1	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. Journal of Allergy and Clinical Immunology, 2017, 140, 950-958.	1.5	1,199
2	EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology, 2012, 50, 1-12.	0.7	1,086
3	Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nature Genetics, 2001, 28, 131-138.	9.4	967
4	Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. Journal of Allergy and Clinical Immunology, 2016, 137, 1449-1456.e4.	1.5	833
5	Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet, The, 2019, 394, 1638-1650.	6.3	812
6	Allergic rhinitis. Lancet, The, 2011, 378, 2112-2122.	6.3	661
7	EAACI Molecular Allergology User's Guide. Pediatric Allergy and Immunology, 2016, 27, 1-250.	1.1	642
8	Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis. JAMA - Journal of the American Medical Association, 2016, 315, 469.	3.8	628
9	Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. Journal of Allergy and Clinical Immunology, 2013, 131, 110-116.e1.	1.5	592
10	European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinology Supplement, 2012, 23, 3 p preceding table of contents, 1-298.	6.0	506
11	IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx?. Respiratory Research, 2006, 7, 135.	1.4	488
12	Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. Journal of Allergy and Clinical Immunology, 2012, 130, 1049-1062.	1.5	486
13	EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 765-798.	2.7	473
14	Endotypes and phenotypes of chronic rhinosinusitis: AÂPRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. Journal of Allergy and Clinical Immunology, 2013, 131, 1479-1490.	1.5	470
15	International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. International Forum of Allergy and Rhinology, 2016, 6, S22-209.	1.5	443
16	International consensus statement on allergy and rhinology: rhinosinusitis 2021. International Forum of Allergy and Rhinology, 2021, 11, 213-739.	1.5	398
17	Interleukin-17 Orchestrates the Granulocyte Influx into Airways after Allergen Inhalation in a Mouse Model of Allergic Asthma. American Journal of Respiratory Cell and Molecular Biology, 2003, 28, 42-50.	1.4	359

18 过æ•å'Œé¼»ç§'å┤国é™…å…±è⁻†å£°æ~Ž∶鼻窦ç,Ž. International Forum of Allergy and Rhinology, 2016, 6, S2⊉5 339

PETER HELLINGS

#	Article	IF	CITATIONS
19	The Lectin-like Domain of Thrombomodulin Confers Protection from Neutrophil-mediated Tissue Damage by Suppressing Adhesion Molecule Expression via Nuclear Factor κB and Mitogen-activated Protein Kinase Pathways. Journal of Experimental Medicine, 2002, 196, 565-577.	4.2	325
20	Oral steroids and doxycycline: Two different approaches to treat nasal polyps. Journal of Allergy and Clinical Immunology, 2010, 125, 1069-1076.e4.	1.5	322
21	Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care. Allergo Journal International, 2017, 26, 16-24.	0.9	292
22	VEGF: A modifier of the del22q11 (DiGeorge) syndrome?. Nature Medicine, 2003, 9, 173-182.	15.2	288
23	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. Journal of Allergy and Clinical Immunology, 2020, 145, 70-80.e3.	1.5	272
24	Paediatric rhinitis: position paper of the <scp>E</scp> uropean <scp>A</scp> cademy of Allergy and <scp>C</scp> linical <scp>I</scp> mmunology. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1102-1116.	2.7	269
25	Histamine Receptor H1–Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome. Gastroenterology, 2016, 150, 875-887.e9.	0.6	263
26	Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis—PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. Journal of Allergy and Clinical Immunology, 2016, 137, 1347-1358.	1.5	249
27	Executive Summary of EPOS 2020 Including Integrated Care Pathways. Rhinology, 2020, 58, 82-111.	0.7	245
28	Impaired barrier function in patients with house dust mite–induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression. Journal of Allergy and Clinical Immunology, 2016, 137, 1043-1053.e5.	1.5	244
29	EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2312-2319.	2.7	239
30	Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and metaâ€analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1597-1631.	2.7	233
31	Nonâ€allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1657-1665.	2.7	193
32	Amphotericin B nasal lavages: Not a solution for patients with chronic rhinosinusitis. Journal of Allergy and Clinical Immunology, 2006, 118, 1149-1156.	1.5	190
33	EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. Journal of Allergy and Clinical Immunology, 2021, 147, 29-36.	1.5	178
34	Epithelial barriers in allergy and asthma. Journal of Allergy and Clinical Immunology, 2020, 145, 1499-1509.	1.5	170
35	Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today?. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1-7.	2.7	169
36	MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1372-1392.	2.7	160

#	Article	IF	CITATIONS
37	Endotype-driven care pathways in patients with chronic rhinosinusitis. Journal of Allergy and Clinical Immunology, 2018, 141, 1543-1551.	1.5	160
38	Diagnostic tools in Rhinology EAACI position paper. Clinical and Translational Allergy, 2011, 1, 2.	1.4	156
39	EPOS Primary Care Guidelines: European Position Paper on the Primary Care Diagnosis and Management of Rhinosinusitis and Nasal Polyps 2007 — a summary. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2008, 17, 79-89.	2.5	154
40	Integrated care pathways for airway diseases (AIRWAYS-ICPs). European Respiratory Journal, 2014, 44, 304-323.	3.1	154
41	The Importance of Local Eosinophilia in the Surgical Outcome of Chronic Rhinosinusitis: A 3-Year Prospective Observational Study. American Journal of Rhinology and Allergy, 2014, 28, 260-264.	1.0	154
42	Lack of efficacy of longâ€ŧerm, lowâ€dose azithromycin in chronic rhinosinusitis: a randomized controlled trial. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1457-1468.	2.7	151
43	2019 ARIA Care pathways for allergen immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2087-2102.	2.7	140
44	Histamine and T helper cytokine–driven epithelial barrier dysfunction in allergic rhinitis. Journal of Allergy and Clinical Immunology, 2018, 141, 951-963.e8.	1.5	139
45	Phenotypes and endotypes of rhinitis and their impact on management: a <scp>PRACTALL</scp> report. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 474-494.	2.7	136
46	Impact of Rhinitis on Work Productivity: A Systematic Review. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1274-1286.e9.	2.0	132
47	Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A <scp>EUFOREA</scp> â€ <scp>ARIA</scp> â€ <scp>EPOS</scp> â€ <scp>AIRWAYS ICP</scp> statement. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1297-1305.	2.7	130
48	Original article: Sinonasal pathology in nonallergic asthma and COPD: â€~united airway disease' beyond the scope of allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 261-267.	2.7	128
49	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2016, 138, 367-374.e2.	1.5	128
50	Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clinical and Translational Allergy, 2012, 2, 21.	1.4	127
51	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clinical and Translational Allergy, 2016, 6, 47.	1.4	121

#	Article	IF	CITATIONS
55	Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clinical and Translational Allergy, 2020, 10, 1.	1.4	110
56	High Prevalence of Body Dysmorphic Disorder Symptoms in Patients Seeking Rhinoplasty. Plastic and Reconstructive Surgery, 2011, 128, 509-517.	0.7	108
57	A wide diversity of bacteria from the human gut produces and degrades biogenic amines. Microbial Ecology in Health and Disease, 2017, 28, 1353881.	3.8	107
58	Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report. Clinical and Translational Allergy, 2017, 7, 17.	1.4	107
59	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. Journal of Allergy and Clinical Immunology, 2019, 143, 864-879.	1.5	103
60	Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. Journal of Allergy and Clinical Immunology, 2019, 144, 135-143.e6.	1.5	101
61	Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 282-290.	2.7	99
62	Allergic rhinitis and its impact on otorhinolaryngology. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 656-664.	2.7	97
63	IL-1β, IL-23, and TGF-β drive plasticity of human ILC2s towards IL-17-producing ILCs in nasal inflammation. Nature Communications, 2019, 10, 2162.	5.8	95
64	The role of mobile health technologies in allergy care: An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 259-272.	2.7	95
65	Treatment of allergic rhinitis using mobile technology with realâ€world data: The <scp>MASK</scp> observational pilot study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1763-1774.	2.7	94
66	Capsaicin treatment reduces nasal hyperreactivity and transient receptor potential cation channel subfamily V,Âreceptor 1 (TRPV1) overexpression in patients with idiopathic rhinitis. Journal of Allergy and Clinical Immunology, 2014, 133, 1332-1339.e3.	1.5	93
67	Pilot study of mobile phone technology in allergic rhinitis in European countries: the <scp>MASK</scp> â€rhinitis study. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 857-865.	2.7	93
68	B7 Interactions with CD28 and CTLA-4 Control Tolerance or Induction of Mucosal Inflammation in Chronic Experimental Colitis. Journal of Immunology, 2001, 167, 1830-1838.	0.4	88
69	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clinical and Translational Allergy, 2019, 9, 44.	1.4	87
70	Progesterone increases airway eosinophilia and hyper-responsiveness in a murine model of allergic asthma. Clinical and Experimental Allergy, 2003, 33, 1457-1463.	1.4	86
71	Biotherapeutics in Chronic Rhinosinusitis with and without Nasal Polyps. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1512-1516.	2.0	86
72	TRPV4 activation triggers protective responses to bacterial lipopolysaccharides in airway epithelial cells. Nature Communications, 2017, 8, 1059.	5.8	86

#	Article	IF	CITATIONS
73	Crucial Role of Transient Receptor Potential Ankyrin 1 and Mast Cells in Induction of Nonallergic Airway Hyperreactivity in Mice. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 486-493.	2.5	85
74	Severe Chronic Allergic (and Related) Diseases: A Uniform Approach – A MeDALL – GA <sup>2</sup> LEN – ARIA Position Paper. International Archives of Allergy and Immunology, 2012, 158, 216-231.	0.9	83
75	Inflammatory Patterns in Upper Airway Disease in the Same Geographical Area may Change over Time. American Journal of Rhinology and Allergy, 2013, 27, 354-360.	1.0	82
76	Blockade of CTLA-4 enhances allergic sensitization and eosinophilic airway inflammation in genetically predisposed mice. European Journal of Immunology, 2002, 32, 585-594.	1.6	81
77	<i>In vivo</i> diagnosis of allergic diseases-allergen provocation tests. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 355-365.	2.7	81
78	Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. Clinical and Translational Allergy, 2019, 9, 16.	1.4	81
79	Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 837-850.	2.7	79
80	Preoperative Symptoms of Body Dysmorphic Disorder Determine Postoperative Satisfaction and Quality of Life in Aesthetic Rhinoplasty. Plastic and Reconstructive Surgery, 2013, 131, 861-868.	0.7	78
81	The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 505-510.	2.7	77
82	Emerging concepts and challenges in implementing the exposome paradigm in allergic diseases and asthma: a Practall document. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 449-463.	2.7	77
83	Long-Term Patient Satisfaction After Revision Rhinoplasty. Laryngoscope, 2007, 117, 985-989.	1.1	76
84	Validation of the <scp>MASK</scp> â€rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control. Clinical and Experimental Allergy, 2017, 47, 1526-1533.	1.4	75
85	Dupilumab improves healthâ€related quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 148-157.	2.7	75
86	Lactobacilli Have a Niche in the Human Nose. Cell Reports, 2020, 31, 107674.	2.9	75
87	Allergen Immunotherapy (AIT): a prototype of Precision Medicine. World Allergy Organization Journal, 2015, 8, 31.	1.6	74
88	Blocking histone deacetylase activity as a novel target for epithelial barrier defects in patients with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2019, 144, 1242-1253.e7.	1.5	74
89	Eosinophilic rhinitis accompanies the development of lower airway inflammation and hyper-reactivity in sensitized mice exposed to aerosolized allergen. Clinical and Experimental Allergy, 2001, 31, 782-790.	1.4	73
90	Adherence to treatment in allergic rhinitis using mobile technology. The <scp>MASK</scp> Study. Clinical and Experimental Allergy, 2019, 49, 442-460.	1.4	73

#	Article	IF	CITATIONS
91	IL-12 Contributes to Allergen-Induced Airway Inflammation in Experimental Asthma. Journal of Immunology, 2006, 177, 6460-6470.	0.4	71
92	The effect of topical amphotericin B on inflammatory markers in patients with chronic rhinosinusitis: A multicenter randomized controlled study. Laryngoscope, 2009, 119, 401-408.	1.1	71
93	A new framework for the interpretation of IgE sensitization tests. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1540-1551.	2.7	71
94	Role of Staphylococcal Superantigens in Airway Disease. International Archives of Allergy and Immunology, 2013, 161, 304-314.	0.9	70
95	Work productivity in rhinitis using cell phones: The <scp>MASK</scp> pilot study. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1475-1484.	2.7	69
96	Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the <scp>MASK</scp> study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1622-1631.	2.7	69
97	Mobile health tools for the management of chronic respiratory diseases. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1292-1306.	2.7	66
98	<i>Staphylococcus aureus</i> enterotoxin B facilitates allergic sensitization in experimental asthma. Clinical and Experimental Allergy, 2010, 40, 1079-1090.	1.4	65
99	Aggravation of bronchial eosinophilia in mice by nasal and bronchial exposure to Staphylococcus aureus enterotoxin B. Clinical and Experimental Allergy, 2006, 36, 1063-1071.	1.4	64
100	Probiotics for the airways: Potential to improve epithelial and immune homeostasis. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1954-1963.	2.7	64
101	Cluster analysis of sputum cytokine-high profiles reveals diversity in T(h)2-high asthma patients. Respiratory Research, 2017, 18, 39.	1.4	63
102	Nasal hyper-reactivity is a common feature in both allergic and nonallergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1427-1434.	2.7	62
103	Nasal obstruction and smell impairment in nasal polyp disease: correlation between objective and subjective parameters. Rhinology, 2010, 48, 426-432.	0.7	60
104	Occupational upper airway disease: how work affects the nose. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 282-291.	2.7	59
105	Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma. Annals of Allergy, Asthma and Immunology, 2021, 126, 584-592.e1.	0.5	59
106	Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2447-2449.e2.	2.0	56
107	Allergic rhinitis and asthma: the link further unraveled. Current Opinion in Pulmonary Medicine, 2003, 9, 46-51.	1.2	54
108	Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly ( <scp>MACVIA</scp> â€ <scp>ARIA</scp> ) ― <scp>EIP</scp> on <scp>AHA</scp> Twinning Reference Site ( <scp>GARD</scp> research demonstration project). Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 77-92.	2.7	54

#	Article	IF	CITATIONS
109	Up-date on neuro-immune mechanisms involved in allergic and non-allergic rhinitis. Rhinology, 2012, 50, 227-235.	0.7	54
110	European position paper on the anatomical terminology of the internal nose and paranasal sinuses. Rhinology Supplement, 2014, 24, 1-34.	6.0	54
111	<scp>ARIA</scp> pharmacy 2018 "Allergic rhinitis care pathways for community pharmacy― Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1219-1236.	2.7	52
112	<i>Staphylococcus aureus</i> enterotoxin B augments granulocyte migration and survival via airway epithelial cell activation. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1013-1020.	2.7	51
113	Genetic evidence for a role of IL33 in nasal polyposis. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 616-622.	2.7	50
114	Screening tools for body dysmorphic disorder in a cosmetic surgery setting. Laryngoscope, 2011, 121, 2535-2541.	1.1	50
115	AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation. European Respiratory Journal, 2016, 47, 1028-1033.	3.1	50
116	A 300 IR sublingual tablet is an effective, safe treatment for house dust mite–induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial. Journal of Allergy and Clinical Immunology, 2021, 147, 1020-1030.e10.	1.5	50
117	Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2461-2471.e5.	2.0	50
118	Explorative study on patient's perceived knowledge level, expectations, preferences and fear of side effects for treatment for allergic rhinitis. Clinical and Translational Allergy, 2012, 2, 9.	1.4	49
119	Damage-associated molecular pattern and innate cytokine release in the airways of competitive swimmers. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 187-194.	2.7	49
120	Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews. Clinical and Translational Allergy, 2017, 7, 24.	1.4	49
121	Google Trends terms reporting rhinitis and related topics differ in European countries. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1261-1266.	2.7	48
122	European Summit on the Prevention and Self-Management of Chronic Respiratory Diseases: report of the European Union Parliament Summit (29 March 2017). Clinical and Translational Allergy, 2017, 7, 49.	1.4	48
123	Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps. International Forum of Allergy and Rhinology, 2021, 11, 1087-1101.	1.5	48
124	Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA. Journal of Nutrition, Health and Aging, 2017, 21, 92-104.	1.5	47
125	Anterior Nares Diversity and Pathobionts Represent Sinus Microbiome in Chronic Rhinosinusitis. MSphere, 2019, 4, .	1.3	47
126	Three-Dimensional Surface Imaging and the Continuous Evolution of Preoperative and Postoperative Assessment in Rhinoplasty. Facial Plastic Surgery, 2016, 32, 088-094.	0.5	46

#	Article	IF	CITATIONS
127	Changing the history of anaphylaxis mortality statistics through the World Health Organization's International Classification of Diseases–11. Journal of Allergy and Clinical Immunology, 2019, 144, 627-633.	1.5	46
128	Body Dysmorphic Disorder in aesthetic rhinoplasty: Validating a new screening tool. Laryngoscope, 2016, 126, 1739-1745.	1.1	45
129	Diagnostic tools in ocular allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1485-1498.	2.7	45
130	Acute and chronic rhinosinusitis and allergic rhinitis in relation to comorbidity, ethnicity and environment. PLoS ONE, 2018, 13, e0192330.	1.1	45
131	Realâ€life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2867-2878.	2.7	45
132	Restoring airway epithelial barrier dysfunction: a new therapeutic challenge in allergic airway disease. Rhinology, 2016, 54, 195-205.	0.7	45
133	Global Airway Disease Beyond Allergy. Current Allergy and Asthma Reports, 2010, 10, 143-149.	2.4	44
134	Nasal hyperreactivity in rhinitis: A diagnostic and therapeutic challenge. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1784-1791.	2.7	44
135	Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2511-2523.	2.0	44
136	Negative impact of occupational exposure on surgical outcome in patients with rhinosinusitis. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 560-565.	2.7	43
137	Visual analogue scale for sino-nasal symptoms severity correlates with sino-nasal outcome test 22: paving the way for a simple outcome tool of CRS burden. Clinical and Translational Allergy, 2018, 8, 32.	1.4	43
138	The golden ratio in facial symmetry. Rhinology, 2013, 51, 18-21.	0.7	42
139	Nasal epithelial barrier dysfunction increases sensitization and mast cell degranulation in the absence of allergic inflammation. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1155-1164.	2.7	42
140	Executive summary of European Task Force document on diagnostic tools in rhinology. Rhinology, 2012, 50, 339-352.	0.7	42
141	Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1086-1095.e5.	2.0	42
142	mySinusitisCoach: patient empowerment in chronic rhinosinusitis using mobile technology. Rhinology, 2018, 56, 209-215.	0.7	41
143	Selective Nasal Allergen Provocation Induces Substance P–Mediated Bronchial Hyperresponsiveness. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 517-523.	1.4	40
144	Shortâ€ŧime cold dry air exposure: A useful diagnostic tool for nasal hyperresponsiveness. Laryngoscope, 2012, 122, 2615-2620.	1.1	40

#	Article	IF	CITATIONS
145	<scp>MP</scp> 29â€02 reduces nasal hyperreactivity and nasal mediators in patients with house dust miteâ€allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1084-1093.	2.7	40
146	Rhinosinusitis and the Lower Airways. Immunology and Allergy Clinics of North America, 2009, 29, 733-740.	0.7	39
147	Prioritizing research challenges and funding for allergy and asthma and the need for translational research—The European Strategic Forum on Allergic Diseases. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2064-2076.	2.7	39
148	Nasobronchial interaction mechanisms in allergic airways disease. Current Opinion in Otolaryngology and Head and Neck Surgery, 2006, 14, 176-182.	0.8	38
149	Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study. Journal of Allergy and Clinical Immunology, 2022, 149, 189-199.	1.5	38
150	CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report. Clinical and Translational Allergy, 2017, 7, 37.	1.4	36
151	Helsinki by nature: The Nature Step to Respiratory Health. Clinical and Translational Allergy, 2019, 9, 57.	1.4	36
152	The effect of systemic treatments on periostin expression reflects their interference with the eosinophilic inflammation in chronic rhinosinusitis with nasal polyps. Rhinology, 2017, 55, 152-160.	0.7	36
153	EUFOREA Rhinology Research Forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis. Rhinology, 2017, 55, 202-210.	0.7	36
154	Vilnius Declaration on chronic respiratory diseases: multisectoral care pathways embedding guided self-management, mHealth and air pollution in chronic respiratory diseases. Clinical and Translational Allergy, 2019, 9, 7.	1.4	35
155	Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study. Clinical and Translational Allergy, 2020, 10, 62.	1.4	34
156	Enhanced chemosensory sensitivity in patients with idiopathic rhinitis and its reversal by nasal capsaicin treatment. Journal of Allergy and Clinical Immunology, 2017, 140, 437-446.e2.	1.5	33
157	Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study. World Allergy Organization Journal, 2018, 11, 15.	1.6	33
158	Personal protection and delivery of rhinologic and endoscopic skull base procedures during the COVID-19 outbreak. Rhinology, 2020, 58, 0-0.	0.7	33
159	Correlation between work impairment, scores of rhinitis severity and asthma using the MASKâ€air <sup>®</sup> App. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1672-1688.	2.7	32
160	Mouse models of global airway allergy: what have we learned and what should we do next?. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 914-919.	2.7	31
161	Secondary Cleft Rhinoplasty. Plastic and Reconstructive Surgery, 2014, 134, 1285-1292.	0.7	31
162	Current controversies and challenges in allergic rhinitis management. Expert Review of Clinical Immunology, 2015, 11, 1205-1217.	1.3	31

#	Article	IF	CITATIONS
163	Capsaicin for Rhinitis. Current Allergy and Asthma Reports, 2016, 16, 60.	2.4	31
164	Placebo effects in allergen immunotherapy—An EAACI Task Force Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 629-647.	2.7	31
165	Realising the potential of mHealth to improve asthma and allergy care: howÂtoÂshape the future. European Respiratory Journal, 2017, 49, 1700447.	3.1	30
166	Surgery in Nasal Polyp Patients: Outcome After a Minimum Observation of 10 Years. American Journal of Rhinology and Allergy, 2021, 35, 449-457.	1.0	30
167	Exacerbation of cigarette smoke-induced pulmonary inflammation by Staphylococcus aureus Enterotoxin B in mice. Respiratory Research, 2011, 12, 69.	1.4	29
168	Evolution of Preoperative Rhinoplasty Consult by Computer Imaging. Facial Plastic Surgery, 2016, 32, 080-087.	0.5	29
169	Quality of life is significantly impaired in nonallergic rhinitis patients. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1094-1100.	2.7	29
170	Immunopathological features of air pollution and its impact on inflammatory airway diseases (IAD). World Allergy Organization Journal, 2020, 13, 100467.	1.6	29
171	Recommendations for the allergy management in the primary care. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 708-718.	2.7	28
172	Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of) Tj ETQqQ Expert Opinion on Pharmacotherapy, 2015, 16, 913-928.	0 0 0 rgBT /0 0.9	verlock 10 Tf 28
173	Assessment of thunderstorm-induced asthma using Google Trends. Journal of Allergy and Clinical Immunology, 2017, 140, 891-893.e7.	1.5	28
174	Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI-Abeforcal-EUFOREA statement. Clinical and Translational Allergy, 2019, 9, 1.	1.4	27
175	High patient satisfaction after secondary rhinoplasty in cleft lip patients. International Forum of Allergy and Rhinology, 2011, 1, 167-172.	1.5	26
176	State-of-the-art overview on biological treatment for CRSwNP. Rhinology, 2021, 59, 0-0.	0.7	26
177	Allergic respiratory disease care in the COVID-19 era: A EUFOREA statement. World Allergy Organization Journal, 2020, 13, 100124.	1.6	25
178	Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies. Clinical and Translational Allergy, 2016, 6, 41.	1.4	24
179	A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. Clinical and Translational Allergy, 2015, 5, 36.	1.4	23
180	Programmed cell deathâ€1 expression correlates with disease severity and ILâ€5 in chronic rhinosinusitis with nasal polyps. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 985-993.	2.7	23

#	Article	IF	CITATIONS
181	Inâ€vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan—An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2161-2169.	2.7	23
182	The pathophysiology of the hygiene hypothesis. International Journal of Pediatric Otorhinolaryngology, 2013, 77, 1065-1071.	0.4	22
183	Transient swelling of the <scp>S</scp> chneiderian membrane after transversal sinus augmentation: a pilot study. Clinical Oral Implants Research, 2014, 25, 36-41.	1.9	22
184	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. Allergo Journal International, 2019, 28, 255-276.	0.9	22
185	Three-dimensional Morphing and Its Added Value in the Rhinoplasty Consult. Plastic and Reconstructive Surgery - Global Open, 2019, 7, e2063.	0.3	22
186	Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. Rhinology, 2019, 58, 0-0.	0.7	21
187	Role of Biologics in Chronic Rhinosinusitis With Nasal Polyposis: State of the Art Review. Otolaryngology - Head and Neck Surgery, 2021, 164, 57-66.	1.1	21
188	Placental Growth Factor Contributes to Bronchial Neutrophilic Inflammation and Edema in Allergic Asthma. American Journal of Respiratory Cell and Molecular Biology, 2012, 46, 781-789.	1.4	20
189	Alcohol hyperâ€responsiveness in chronic rhinosinusitis with nasal polyps. Clinical and Experimental Allergy, 2017, 47, 245-253.	1.4	20
190	Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP. Rhinology, 2021, 59, 0-0.	0.7	20
191	SCUAD and chronic rhinosinusitis. Reinforcing hypothesis driven research in difficult cases. Rhinology, 2014, 52, 3-8.	0.7	19
192	Nasal corticosteroid treatment reduces substance P levels in tear fluid in allergic rhinoconjunctivitis. Annals of Allergy, Asthma and Immunology, 2012, 109, 141-146.	0.5	18
193	Prevalence and determinants of allergic diseases in a Congolese population. International Forum of Allergy and Rhinology, 2012, 2, 285-293.	1.5	18
194	Lolium perenne peptides for treatment of grass pollen allergy: AÂrandomized, double-blind, placebo-controlled clinical trial. Journal of Allergy and Clinical Immunology, 2018, 141, 448-451.	1.5	18
195	Conjunctival effects of a selective nasal pollen provocation. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1173-1181.	2.7	17
196	A chest physician's guide to mechanisms of sinonasal disease. Thorax, 2015, 70, 353-358.	2.7	17
197	From ARIA guidelines to the digital transformation of health in rhinitis and asthma multimorbidity. European Respiratory Journal, 2019, 54, 1901023.	3.1	17
198	Patients Unmet Needs in Chronic Rhinosinusitis With Nasal Polyps Care: A Patient Advisory Board Statement of EUFOREA. Frontiers in Allergy, 2021, 2, 761388.	1.2	17

#	Article	lF	CITATIONS
199	The effect of systemic treatments on periostin expression reflects their interference with the eosinophilic inflammation in chronic rhinosinusitis with nasal polyps. Rhinology, 2017, 55, .	0.7	16
200	The Role of Biologics in Chronic Rhinosinusitis with Nasal Polyps. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1099-1106.	2.0	16
201	Airway exposure to hypochlorite prior to ovalbumin induces airway hyperreactivity without evidence for allergic sensitization. Toxicology Letters, 2011, 204, 101-107.	0.4	15
202	Calu-3 epithelial cells exhibit different immune and epithelial barrier responses from freshly isolated primary nasal epithelial cells in vitro. Clinical and Translational Allergy, 2018, 8, 40.	1.4	15
203	The nasal mutualist Dolosigranulum pigrum AMBR11 supports homeostasis via multiple mechanisms. IScience, 2021, 24, 102978.	1.9	15
204	White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA. Frontiers in Allergy, 2022, 3, .	1.2	15
205	IL-10- and IL-12-Independent Down-Regulation of Allergic Sensitization by Stimulation of CD40 Signaling. Journal of Immunology, 2006, 177, 5138-5144.	0.4	14
206	Rapid systemic uptake of allergens through the respiratory mucosa. Journal of Allergy and Clinical Immunology, 2007, 120, 472-474.	1.5	14
207	Nonmelanoma Skin Cancer of the Head and Neck. Facial Plastic Surgery Clinics of North America, 2012, 20, 445-454.	0.9	14
208	Vascular endothelial growth factor receptor 1 expression in nasal polyp tissue. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 237-245.	2.7	14
209	Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review. Clinical and Translational Allergy, 2016, 6, 12.	1.4	14
210	Recent pharmacological developments in the treatment of perennial and persistent allergic rhinitis. Expert Opinion on Pharmacotherapy, 2016, 17, 657-669.	0.9	14
211	A possible role of stem cells in nasal polyposis. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1868-1873.	2.7	14
212	Prevalence and impact of nasal hyperreactivity in chronic rhinosinusitis. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1768-1771.	2.7	14
213	Dexamethasone-induced apoptosis of freshly isolated human nasal epithelial cells concomitant with abrogation of IL-8 production. Rhinology, 2010, 48, 401-407.	0.7	14
214	Allergen provocation tests in respiratory research: building on 50 years of experience. European Respiratory Journal, 2022, 60, 2102782.	3.1	14
215	The nose: gatekeeper and trigger of bronchial disease. Rhinology, 2006, 44, 179-87.	0.7	14
216	Rhinoplasty from a Rhinologist's Perspective: Need for Recognition of Associated Sinonasal Conditions. American Journal of Rhinology and Allergy, 2012, 26, 493-496.	1.0	13

#	Article	IF	CITATIONS
217	Prevention of chronic rhinosinusitis. Rhinology, 2018, 56, 307-315.	0.7	13
218	Rhinology Future Debates, an EUFOREA Report. Rhinology, 2017, 55, 298-304.	0.7	13
219	Epithelial and sensory mechanisms of nasal hyperreactivity. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1450-1463.	2.7	13
220	Laryngeal effects of nasal allergen provocation in singers with allergic rhinitis. European Archives of Oto-Rhino-Laryngology, 2011, 268, 419-427.	0.8	12
221	No Mucosal Atrophy and Reduced Inflammatory Cells: Active-controlled Trial with Yearlong Fluticasone Furoate Nasal Spray. American Journal of Rhinology and Allergy, 2012, 26, 36-44.	1.0	12
222	A TRiP Through the Roles of Transient Receptor Potential Cation Channels in Type 2 Upper Airway Inflammation. Current Allergy and Asthma Reports, 2021, 21, 20.	2.4	12
223	Nasal Allergen Deposition Leads to Conjunctival Mast Cell Degranulation in Allergic Rhinoconjunctivitis. American Journal of Rhinology and Allergy, 2014, 28, 290-296.	1.0	11
224	Therapeutic effect of capsaicin nasal treatment in patients with mixed rhinitis unresponsive to intranasal steroids. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 248-250.	2.7	11
225	<i>Lacticaseibacillus casei</i> AMBR2 Restores Airway Epithelial Integrity in Chronic Rhinosinusitis With Nasal Polyps. Allergy, Asthma and Immunology Research, 2021, 13, 560.	1.1	11
226	The influence of European legislation on the use of diagnostic test allergens for nasal allergen provocation in routine care of patients with allergic rhinitis. Rhinology, 2015, 53, 260-269.	0.7	11
227	T-cell mediated late increase in bronchial tone after allergen provocation in a murine asthma model. Clinical Immunology, 2008, 128, 248-258.	1.4	10
228	Sensitization Rate and Clinical Profile of Congolese Patients with Rhinitis. Allergy and Rhinology, 2012, 3, ar.2012.3.0023.	0.7	10
229	Rhinology future trends: 2017 EUFOREA debate on allergic rhinitis. Rhinology, 2019, 57, 49-56.	0.7	10
230	Effect of the tongue-in-groove technique on the smile form. Rhinology, 2020, 58, 626-628.	0.7	10
231	WAO-ARIA consensus on chronic cough - Part II: Phenotypes and mechanisms of abnormal cough presentation $\hat{a} \in $ " Updates in COVID-19. World Allergy Organization Journal, 2021, 14, 100618.	1.6	10
232	What we should learn from the London Olympics. Current Opinion in Allergy and Clinical Immunology, 2013, 13, 1-3.	1.1	9
233	Regulation of melanocortin 1 receptor in allergic rhinitis <i>in vitro</i> and <i>in vivo</i> . Clinical and Experimental Allergy, 2016, 46, 1066-1074.	1.4	9
234	Exercise and Sinonasal Disease. Immunology and Allergy Clinics of North America, 2018, 38, 259-269.	0.7	9

#	Article	IF	CITATIONS
235	Highlights and recent developments in airway diseases in EAACI journals (2017). Clinical and Translational Allergy, 2018, 8, 49.	1.4	9
236	Nasal symptoms, epithelial injury and neurogenic inflammation in elite swimmers. Rhinology, 2018, 56, 279-287.	0.7	9
237	Multidisciplinary Care for Severe or Uncontrolled Chronic Upper Airway Diseases. Current Allergy and Asthma Reports, 2021, 21, 27.	2.4	9
238	A multicenter realâ€life study on the multiple reasons for uncontrolled allergic rhinitis. International Forum of Allergy and Rhinology, 2021, 11, 1452-1460.	1.5	9
239	Prevalence and triggers of self-reported nasal hyperreactivity in adults with asthma. World Allergy Organization Journal, 2020, 13, 100132.	1.6	9
240	Managing nasal valve compromise patients with nasal dilators: objective vs. subjective parameters. Rhinology, 2016, 54, 348-354.	0.7	9
241	Real-life study showing better control of allergic rhinitis by immunotherapy than regular pharmacotherapy. Rhinology, 2016, 54, 214-220.	0.7	9
242	Estimating Clinically Meaningful Change of Efficacy Outcomes in Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyposis. Laryngoscope, 2022, 132, 265-271.	1.1	9
243	Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design. American Journal of Rhinology and Allergy, 2022, 36, 788-795.	1.0	9
244	Omalizumab Is Effective In Allergic And Non-allergic Patients With Nasal Polyps And Asthma. Journal of Allergy and Clinical Immunology, 2012, 129, AB69.	1.5	8
245	Effect of Nasal Anti-Inflammatory Treatment in Chronic Obstructive Pulmonary Disease. American Journal of Rhinology and Allergy, 2013, 27, 273-277.	1.0	8
246	Nasal and ocular responses after specific and nonspecific nasal challenges in seasonal allergic rhinitis. Annals of Allergy, Asthma and Immunology, 2016, 116, 199-205.	0.5	8
247	Serum and sputum calprotectin, a reflection of neutrophilic airway inflammation in asthmatics after highâ€eltitude exposure. Clinical and Experimental Allergy, 2017, 47, 1675-1677.	1.4	8
248	Highlights and recent developments in food and drug allergy, and anaphylaxis in EAACI Journals (2017). Pediatric Allergy and Immunology, 2018, 29, 801-807.	1.1	8
249	Patient Advisory Board for Chronic Rhinosinusitis – A EUFOREA initiative. Rhinology, 2019, 57, 0-0.	0.7	8
250	Mometasone furoate and fluticasone furoate are equally effective in restoring nasal epithelial barrier dysfunction in allergic rhinitis. World Allergy Organization Journal, 2021, 14, 100585.	1.6	8
251	Dupilumab in <scp>CRSwNP</scp> : Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds. Laryngoscope, 2022, 132, 259-264.	1.1	8
252	Occupational exposure influences control of disease in patients with chronic rhinosinusitis. Rhinology, 2021, 59, 380-386.	0.7	8

#	Article	lF	CITATIONS
253	SWOT Analysis of Chronic Rhinosinusitis Care Anno 2022. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1468-1471.	2.0	8
254	Impact of changed legislation on skin tests: the present and future. Current Opinion in Allergy and Clinical Immunology, 2016, 16, 465-468.	1.1	7
255	Low-dose capsaicin (0.01 mM) nasal spray is equally effective as the current standard treatment for idiopathic rhinitis: AArandomized, double-blind, placebo-controlled trial. Journal of Allergy and Clinical Immunology, 2021, 147, 397-400.e4.	1.5	7
256	Objective measurements of nasal function: necessary before nasal surgery?. Rhinology, 2014, 52, 289-291.	0.7	7
257	ARIA masterclass 2018: From guidelines to real-life implementation. Rhinology, 2019, 57, 0-0.	0.7	6
258	Selfâ€reported nasal hyperreactivity is common in all chronic upper airway inflammatory phenotypes and not related to general wellâ€being. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3806-3809.	2.7	6
259	Improvement of nasal breathing and patient satisfaction by the endonasal dilator Airmax®. Rhinology, 2014, 52, 31-34.	0.7	6
260	Dupilumab Improves Sense of Smell and Reduces Anosmia Among Patients with Nasal Polyposis and Chronic Sinusitis: Results from a Phase 2a Trial. Journal of Allergy and Clinical Immunology, 2017, 139, AB90.	1.5	5
261	Brain activation after nasal histamine provocation in house dust mite allergic rhinitis patients. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1879-1882.	2.7	5
262	Therapy of allergic rhinitis in routine care: evidence-based benefit assessment of freely combined use of various active ingredients. Allergo Journal International, 2020, 29, 129-138.	0.9	5
263	From ancient Greek medicine to EP³OS. Rhinology, 2010, 48, 265-272.	0.7	5
264	The â€~GA²LEN Sinusitis Cohort': an introduction. Clinical and Translational Allergy, 2015, 5, O1.	1.4	4
265	Prediction and prevention of allergy and asthma in EAACI journals (2016). Clinical and Translational Allergy, 2017, 7, 46.	1.4	4
266	Entering a new era of Predictive Medicine in Rhinology. Rhinology, 2018, 56, 97-98.	0.7	4
267	Short and longâ€ŧerm safety of MP29â€02*: a new therapy for the treatment of allergic rhinitis. Clinical and Translational Allergy, 2013, 3, O15.	1.4	3
268	EUFOREA Rhinology Research Forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis. Rhinology, 2017, 55, .	0.7	3
269	Rhinology Future Debates 2017 by <scp>EUFOREA</scp> : Novel treatments and surgical solutions in rhinology. Clinical Otolaryngology, 2018, 43, 1429-1438.	0.6	3
270	Rhinology in the forefront of European political attention. Rhinology, 2015, 53, 289-289.	0.7	3

#	Article	IF	CITATIONS
271	ARIA 2016: Integrated care pathways for predictive medicine across the life cycle. Russian Journal of Allergy, 2017, 14, 46-54.	0.1	3
272	Medical therapy and smell dysfunction. , 2009, 5 Suppl 13, 71-5.		3
273	Pattern of uncontrolled allergic rhinitis in a hospital setting of Kinshasa, Democratic Republic of Congo. Immunity, Inflammation and Disease, 2019, 7, 286-291.	1.3	2
274	Much ado about Biologicals: <i>Highlights of the Master Class on Biologicals, Prague, 2018</i> . Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 837-840.	2.7	2
275	2019 ARIA Care Pathways for Allergic Rhinitis-Turkey. Turkish Thoracic Journal, 2020, 21, 122-133.	0.2	2
276	Quality of life and use of medication in chronic allergic and nonâ€allergic rhinitis patients. Clinical and Translational Allergy, 2013, 3, O4.	1.4	1
277	New Findings in Nonallergic Rhinitis and Local Allergic Rhinitis. Current Otorhinolaryngology Reports, 2013, 1, 106-112.	0.2	1
278	Reply. Journal of Allergy and Clinical Immunology, 2013, 132, 247-248.	1.5	1
279	Are Systemic Antibiotics Indicated in Aesthetic Breast Surgery? A Systematic Review of the Literature. Plastic and Reconstructive Surgery, 2014, 133, 62e-63e.	0.7	1
280	A new allergic rhinitis therapy (MP29â€02*) provides effective and rapid symptom relief for patients who suffer most from the bothersome symptoms of nasal congestion or ocular itch. Clinical and Translational Allergy, 2015, 5, P33.	1.4	1
281	MP29â€02*'s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis. Clinical and Translational Allergy, 2015, 5, P36.	1.4	1
282	A new intranasal therapy (MP29â€02*) is more effective than current firstline therapy regardless of season, symptom or severity Clinical and Translational Allergy, 2015, 5, P38.	1.4	1
283	Olfactory function in patients with nonsyndromic orofacial clefts and their unaffected relatives. American Journal of Medical Genetics, Part A, 2018, 176, 2375-2381.	0.7	1
284	Endotype-Driven Approach in Rhinitis. , 2019, , 59-61.		1
285	EUFOREA Approach to Precision Medicine in Respiratory Diseases. , 2019, , 207-211.		1
286	From prevention to optimal treatment in chronic rhinosinusitis. Rhinology, 2018, 56, 305-306.	0.7	1
287	Pulmonary Neuroepithelial Bodies as Hypothetical Immunomodulators. , 2009, , 311-330.		1
288	Paving the future of rhinosinusitis care. Rhinology, 2017, 55, 193-194.	0.7	1

#	Article	IF	CITATIONS
289	Joint action with European CRSwNP Patients for better outcomes. Rhinology, 2019, 57, 321-321.	0.7	1
290	Unique approach to secondary cleft-lip rhinoplasty in facial plastic surgery. , 2010, 6 Suppl 15, 97-101.		1
291	Sensitization to common aeroallergens in patients at an outpatient ENT clinic. , 2011, 7, 79-85.		1
292	499 Neutralization of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) during sensitization or challenge has opposite effects on IgE production in a mouse model of allergic asthma. Journal of Allergy and Clinical Immunology, 2000, 105, S164.	1.5	0
293	Depleting anti-CD4 monoclonal antibody inhibits the bronchial late phase response in a mouse model of asthma*1. Journal of Allergy and Clinical Immunology, 2004, 113, S195.	1.5	о
294	Role of Staphylococcus Aureus Enterotoxin B in allergic sensitization. Journal of Allergy and Clinical Immunology, 2009, 123, S69-S69.	1.5	0
295	A new therapy (MP29â€02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity. Clinical and Translational Allergy, 2013, 3, O16.	1.4	0
296	A new efficacy parameter (complete/near complete symptom relief) in allergic rhinitis management: results with a new therapy MP29â€02*. Clinical and Translational Allergy, 2013, 3, P42.	1.4	0
297	Longâ€ŧerm control in chronic rhinosinusitis after endoscopic sinus surgery. Clinical and Translational Allergy, 2013, 3, P44.	1.4	0
298	A new therapy (MP29â€02*) effectively treats patients with seasonal allergic rhinitis who suffer most from the bothersome nasal symptom of congestion. Clinical and Translational Allergy, 2013, 3, P39.	1.4	0
299	A new therapy (MP29â€02*) effectively targets the entire seasonal allergic rhinitis symptom complex. Clinical and Translational Allergy, 2013, 3, P45.	1.4	0
300	Nasal NO and Its Role in the Physiology of the Nose and Diagnosis. , 2013, , 109-112.		0
301	Immunogenicity Evaluation of Subcutaneous Administration of Peptide Hydrolysate from Lolium Perenne (gpASIT+â,,¢) in Combination with Bacterial HSP70 (DnaK) in Patients with Seasonal Allergic Rhinitis: A Double Blind Placebo Controlled Trial. Journal of Allergy and Clinical Immunology, 2015, 135. AB159.	1.5	0
302	A new allergic rhinitis therapy (MP29â€02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies. Clinical and Translational Allergy, 2015, 5, P34.	1.4	0
303	Identification of gaps in the current allergic rhinitis guidelines and how these can be filled. Clinical and Translational Allergy, 2015, 5, P39.	1.4	Ο
304	The importance of local eosinophilia in the surgical outcome of chronic rhinosinusitis: a 3-year prospective observational study. Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology), 2016, 55, 127-127.	0.0	0
305	ARIA 2016 executive summary: Integrated care pathways for predictive, preventive and personalized medicine across the life cycle. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 78-83.	0.2	0
306	Paving the post-covid Rhinology era with ERS!. Rhinology, 2021, 59, 225-225.	0.7	0

#	Article	IF	CITATIONS
307	Umsetzung der Strategien des Programms "Chronische Atemwegserkrankungen" der Europächen Innovationspartnerschaft "Aktives und gesundes Altern" – Executive Summary. Allergologie, 2017, 40, 219-226.	0.1	Ο
308	Nasal polyposis and asthma: the otorhinolaryngologist's view. , 0, , 87-104.		0
309	Treating the nose for controlling the lung: a vanishing story?. , 0, , 177-192.		0